Join our daily newsletter At The Bell to receive exclusive market insights
Amaero International Ltd (3DA) has secured $11 million to finalise the installation and commissioning of the titanium alloy powder plant the company’s banking on to take it to a cashflow-positive position.
The 3D additive manufacturing company is also looking to use the funds to pursue US growth opportunities.
Amaero raised $8.2 million through a placement to institutional investors at an undiscounted issue price of 21 cents per share. The remainder came via a senior convertible note issued to Pegasus Growth Capital Fund (PGCFI) — the company which led the placement.
Amaero International Chair David Hanna said Pegasus Managing Director Hank Holland would join Amaero’s board.
“As a trusted and respected player with incredibly strong prospects in the rapidly evolving 3D/additive manufacturing market, we look forward to pursuing additional strategic transactions to maximise value for our shareholders,” he said.
In the wake of the news, Amaero shares have been trading up about 12 per cent at 23.5 cents as of 2:14 pm AEST.
Tombola Gold (TBA) has cashed up through a second capital raising within three months.
This time the company has secured $10.5 million in a placement to institutional and sophisticated investors priced at 6 cents — more than double the price of shares offered in February’s $3 million raise.
Tombola’s Managing Director, Byron Miles, said the money meant the company’s flagship Mount Freda Gold Mine was now financed through to first gold production — a milestone that remains on track to occur next quarter.
You can watch our interview with Byron Miles here at The Deal Room.
The company has a market cap of about $50 million and shares have been trading at 5.9 cents at 2:19 pm AEST.
Clinical-stage cannabinoid and psychedelic pharmaceutical company Incannex (IHL) will be issuing more than 218-million new shares at 57.3 cents in return for 100 per cent of APIRx Pharmaceuticals USA.
The scrip acquisition equates to a $125 million deal.
Incannex CEO and MD Joel Latham said the agreement would present near- and long-term opportunities for value growth.
APIRx has therapeutic candidates for applications including Parkinson’s disease, restless leg syndrome and the treatment of pain, skin and eye conditions.
The sale is set to be complete before the end of the financial year. Incannex has a market cap approaching half a billion dollars and shares traded up more than 10 per cent today at 40.5 cents at 2:20 pm AEST.
Finally, Tyranna Resources (TYX) entered a trading halt ahead of capital raising for a proposed project acquisition. The details are scheduled to be released by Monday.
